An experimental RNA-based drug acts by using genetic material
called targeting RNA, to enter cancer cells, and another type, called
silencing RNA , to stop the expression of a protein that keeps the cells
alive, thereby destroying prostate cancer cells leaving normal cells
unharmed.
The drug, developed at Duke University Medical Center, uses one type of genetic material, called In tests in mice with prostate cancer, the drug shrank the size of their tumors by half, while the tumors in control mice that did not receive the drug continued to grow, said study co-author Bruce Sullenger, Ph.D., director of Duke's Translational Research Institute and chief of the Division of Experimental Surgery.
The drug, developed at Duke University Medical Center, uses one type of genetic material, called In tests in mice with prostate cancer, the drug shrank the size of their tumors by half, while the tumors in control mice that did not receive the drug continued to grow, said study co-author Bruce Sullenger, Ph.D., director of Duke's Translational Research Institute and chief of the Division of Experimental Surgery.
The mice showed no side effects from the treatment, Sullenger said.
- << Four-Drug AIDS Treatment Regimen Deemed Of No Use
- Women Prefer Office Procedure during treatment of Early Preg... >>
Recommended Reading
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse.
Prostate Cancer
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can help both in early detection and effective treatment
